Literature DB >> 10548201

Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin.

F M Brunkhorst1, O K Eberhard, R Brunkhorst.   

Abstract

OBJECTIVE: To test the sepsis marker procalcitonin (PCT) for its applicability to discriminate between septic and nonseptic causes of acute respiratory distress syndrome (ARDS).
DESIGN: Prospective study, assessing the course of PCT serum levels in early (within 72 hrs after onset) ARDS. The three other inflammation markers neopterin, interleukin-6 (IL-6), and C-reactive protein (CRP) were tested in parallel.
SETTING: Twenty-four-bed medical intensive care unit of a 1,990-bed primary hospital, providing health care for an estimated 39,000 patients. PATIENTS: Twenty-seven patients, 18 male and nine female, aged 16-85 yrs, with early ARDS of known cause (17 with septic and ten with nonseptic ARDS) were enrolled in a prospective study between May 1994 and May 1995.
INTERVENTIONS: Serum samples were drawn every 4-6 hrs for measurement of PCT, neopterin, IL-6, and CRP concentrations. Blood cultures, tracheal aspirates, and urine samples were obtained every 12-24 hrs. In 24 of 27 patients, bronchoscopic cultures were also obtained. Clinical sepsis criteria as defined by the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference were checked daily.
MEASUREMENTS AND MAIN RESULTS: Assessment of inflammation marker serum levels in septic vs. nonseptic ARDS. PCT serum levels were significantly higher (p < .0005) in the patients with septic ARDS than in patients with nonseptic ARDS within 72 hrs after onset of ARDS. There was no overlap between the two groups. Also, neopterin allowed a differentiation (p < .005), although a substantial overlap between serum levels of septic and nonseptic patients was observed. No discrimination could be achieved by determination of CRP and IL-6 levels.
CONCLUSION: PCT determination in early ARDS could help to discriminate between septic and nonseptic underlying disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10548201     DOI: 10.1097/00003246-199910000-00016

Source DB:  PubMed          Journal:  Crit Care Med        ISSN: 0090-3493            Impact factor:   7.598


  40 in total

1.  Clinical characteristics and outcomes of sepsis-related vs non-sepsis-related ARDS.

Authors:  Chau-Chyun Sheu; Michelle N Gong; Rihong Zhai; Feng Chen; Ednan K Bajwa; Peter F Clardy; Diana C Gallagher; B Taylor Thompson; David C Christiani
Journal:  Chest       Date:  2010-05-27       Impact factor: 9.410

2.  Legionella pneumonia and serum procalcitonin.

Authors:  Laura Franzin; Daniela Cabodi
Journal:  Curr Microbiol       Date:  2004-10-28       Impact factor: 2.188

3.  Altered levels of soluble CD18 may associate immune mechanisms with outcome in sepsis.

Authors:  T W Kragstrup; K Juul-Madsen; S H Christiansen; X Zhang; J Krog; T Vorup-Jensen; A G Kjaergaard
Journal:  Clin Exp Immunol       Date:  2017-08-07       Impact factor: 4.330

Review 4.  Biomarker discovery and development in pediatric critical care medicine.

Authors:  Jennifer M Kaplan; Hector R Wong
Journal:  Pediatr Crit Care Med       Date:  2011-03       Impact factor: 3.624

Review 5.  [Sepsis. Update on pathophysiology, diagnostics and therapy].

Authors:  M Bauer; F Brunkhorst; T Welte; H Gerlach; K Reinhart
Journal:  Anaesthesist       Date:  2006-08       Impact factor: 1.041

Review 6.  Emerging infection and sepsis biomarkers: will they change current therapies?

Authors:  Lauren Jacobs; Hector R Wong
Journal:  Expert Rev Anti Infect Ther       Date:  2016-08-17       Impact factor: 5.091

7.  [Impairment of oxygenation of patients in surgical intensive care : Early symptom of severe sepsis].

Authors:  M Hückstädt; G O Hofmann; T Mendel; R Stuttmann; P Hilbert-Carius
Journal:  Anaesthesist       Date:  2016-10-05       Impact factor: 1.041

8.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

9.  Activated partial thromboplastin time waveform analysis as specific sepsis marker in cardiopulmonary bypass surgery.

Authors:  Christian P Schneider; Martin K Angele; Wolfgang H Hartl
Journal:  Crit Care       Date:  2010-01-21       Impact factor: 9.097

10.  Value of serum procalcitonin in evaluating the prognosis of sepsis in elderly patients with colorectal cancer undergoing emergency colorectal surgery.

Authors:  Yong Li; Zhao-Chen Jin; Yan Cai; Mu-Sen Ji; Jing Liu
Journal:  Indian J Surg       Date:  2012-06-28       Impact factor: 0.656

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.